Zhejiang Jiuzhou Pharmaceutical announced that its subsidiary, Jiuzhou Biotech, recently received the approval and issuance of the registration certificate for oxcarbazepine tablets from the National Medical Products Administration. Oxcarbazepine tablets are used to treat primary generalized tonic-clonic seizures and partial seizures, with a total sales of over 0.8 billion yuan in 2023 in China's three major terminals and six major markets.
九洲药业：控股子公司获药品注册证书
Zhejiang Jiuzhou Pharmaceutical: Subsidiary holding obtained pharmaceutical registration certificate.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.